We demonstrated that, in contrast to classical opioid receptors, ACKR3 won't result in classical G protein signaling and isn't modulated by the classical prescription or analgesic opioids, like morphine, fentanyl, or buprenorphine, or by nonselective opioid antagonists like naloxone. Instead, we established that LIH383, an ACKR3-selective subnanomolar competitor peptide, https://jamesw260urj7.actoblog.com/profile